Generation of a Danish TTO value set for EQ-5D health states

Scandinavian Journal of Public Health

Volumn 37, Issue 5, 2009, Pages 459-466

  Wittrup Jensen, Kim U ^a   Lauridsen, Jørgen ^b   Pedersen, Kjeld M ^b   Gudex, Claire ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Denmark; EQ 5D; health state preferences; time trade off; utilities

Indexed keywords

ADULT; ARTICLE; COMPUTER ANALYSIS; CONTROLLED STUDY; COST UTILITY ANALYSIS; DENMARK; EQ 5D; FEMALE; HEALTH ECONOMICS; HEALTH STATUS; HEALTH SURVEY; HUMAN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; REFERENCE VALUE; REGRESSION ANALYSIS;

ADULT; COST-BENEFIT ANALYSIS; DENMARK; FEMALE; HEALTH POLICY; HEALTH STATUS; HEALTH SURVEYS; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); QUALITY OF LIFE; QUESTIONNAIRES; SELF CONCEPT; TIME FACTORS;

EID: 67651124640     PISSN: 14034948     EISSN: None     Source Type: Journal    
DOI: 10.1177/1403494809105287     Document Type: Article

References (28)

1. National Institute for Clinical Excellence. Guide to the methods of technology appraisal (reference N0515). http://www.nice.org.uk/niceMedia/pdf/TAP_Methods.pdf. 2004 (accessed 20th January 2009).
2. Weinstein M.C., Siegel J.E., Gold M.R., Kamlet M.S., Russell L.B. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276(15):1253-8.
3. Health Technology Assessment Handbook. Copenhagen: Danish Centre for Health Technology Assessment, National Board of Health; 2007.
4. Brooks R., Rabin R., de Charro F. The measurement and valuation of health status using EQ-5D: a European perspective. Dordrecht: Kluwer Academic Publishers, 2003.
5. Rabin R., de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33(5):337-343.
6. Gudex C., Sorensen J. EQ-SD: A generic health status instrument. Månedsskrift for Praktisk Lægegerning 1998; 76:1339-1345.
7. Gudex C., Thygesen V., Vestergaard M., Jespersen B. [Validation of the Danish EQ-SD]. Hillerød, Denmark: Psychiatric Research Unit, Frederiksborg General Hospital; 1999.
8. Bronnum-Hansen H., Juel K., Davidsen M., Sorensen J. Impact of selected risk factors on quality-adjusted life expectancy in Denmark. Scand J Public Health 2007;35(5): 510-515.
9. Soegaard R., Bunger C.E., Christiansen T., Hoy K., Eiskjaer S.P., Christensen F.B. Circumferential fusion is dominant over posterolateral fusion in a long-term perspective: cost-utility evaluation of a randomized controlled trial in severe, chronic low back pain. Spine 2007;32(22):2405-2414.
10. Kessing L.V., Hansen H.V., Bech P. General health and well-being in outpatients with depressive and bipolar disorders. Nord J Psychiatry 2006;60(2):150-6.
11. Waldorff F.B., Rishoj S., Waldemar G. If you don't ask (about memory), they probably won't tell. J Fam Pract 2008; 57(1):41-44.
12. Dolan P., Gudex C., Kind P., Williams A. The time trade-off method: results from a general population study. Health Econ 1996;5(2):141-154.
13. Badia X., Roset M., Herdman M., Kind P. A comparison of United Kingdom and Spanish general population time trade-off values for EQ-5D health states. Med Decis Making 2001;21(1):7-16.
14. Lamers L.M., McDonnell J., Stalmeier P.F., Krabbe P.F., Busschbach J.J. The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006;15(10):1121-1132.
15. Tsuchiya A., Ikeda S., Ikegami N., Nishimura S., Sakai I., Fukuda T., et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ 2002;11(4):341-353.
16. Szende A., Oppe M., Devlin N. EQ-5D value sets: inventory, comparative review and user guide. Dordrecht: Springer, 2007.
17. Pedersen K.M., Wittrup-Jensen K., Brooks R., Gudex C. Værdisætning af sundhed: teorien om kvalitetsjusterede leveår og en dansk anvendelse [Valuation of health: theory related to quality-adjusted life years and a Danish application]. Odense: Syddansk Universitetsforlag, 2006.
18. Wittrup-Jensen K.U., Lauridsen J., Pedersen K.M. Modelling Danish EuroQol (EQ-5D) tariffs by applying the time trade-off method. Health Economics Working Paper 2008:4. Odense: University of Southern Denmark, Research Unit of Health Economics (www.healtheconomics.dk - under Research publications); 2008 (accessed 20th January 2009).
19. Torrance G.W. Measurement of health state utilities for economic appraisal. J Health Econ 1986;5(1):1-30.
20. Dolan P. Modelling valuations for EuroQol health states. Med Care 1997;35(11):1095-1108.
21. Busschbach J.J., McDonnell J., Essink-Bot ML, van Hout B.A. Estimating parametric relationships between health description and health valuation with an application to the EuroQol EQ-5D. J Health Econ 1999;18(5):551-571.
22. SAS Institute Staff. SAS/STAT User's guide Version 8. New York: Fatbrain, 2000.
23. Rabe-Hesketh S., Everitt B. A handbook of statistical analyses using STATA. New York: CRC Press, 2000.
24. Devlin N.J., Hansen P., Kind P., Williams A. The health state preferences and logical inconsistencies of New Zealanders: a tale of two tariffs. Centre for Health Economics, York, UK, and University of Otago, NZ; 2000. Report No. 180.
25. Prevolnik R.V., Rebolj M. The Slovenian VAS tariff based on valuations of EQ-5D health states from the general population. In: Cabasés JM, Gaminde I, editors. 17th Plenary Meeting of the EuroQol Group Discussion Papers. Pamplona, Spain: 2000.
26. Badia X., Herdman M., Kind P. The influence of ill-health experience on the valuation of health. Pharmacoeconomics 1998;13(6):687-696.
27. Dolan P., Roberts J. To what extent can we explain time trade-off values from other information about respondents? Soc Sci Med 2002;54(6):919-929.
28. Essink-Bot ML, Stuifbergen M.C., Meerding W.J., Looman C.W., Bonsel G.J. Individual differences in the use of the response scale determine valuations of hypothetical health states: an empirical study. BMC Health Serv Res 2007;7:62.